O	0	7	Subject	Subject	NN	B-NP
O	8	19	disposition	disposition	NN	I-NP
O	19	20	.	.	.	O

O	21	25	Data	Datum	NNS	B-NP
O	26	30	from	from	IN	B-PP
O	31	34	110	110	CD	B-NP
O	35	43	enrolled	enrolled	JJ	I-NP
O	44	52	subjects	subject	NNS	I-NP
O	53	57	were	be	VBD	B-VP
O	58	66	eligible	eligible	JJ	B-ADJP
O	67	70	for	for	IN	B-PP
O	71	79	analysis	analysis	NN	B-NP
O	79	80	.	.	.	O

O	81	84	The	The	DT	B-NP
O	85	97	demographics	demographic	NNS	I-NP
O	98	100	of	of	IN	B-PP
O	101	104	the	the	DT	B-NP
O	105	110	study	study	NN	I-NP
O	111	119	subjects	subject	NNS	I-NP
O	119	120	,	,	,	O
O	121	123	by	by	IN	B-PP
O	124	128	site	site	NN	B-NP
O	128	129	,	,	,	O
O	130	133	are	be	VBP	B-VP
O	134	142	recorded	record	VBN	I-VP
O	143	145	in	in	IN	B-PP
O	146	151	Table	Table	JJ	B-NP
O	152	153	1	1	CD	I-NP
O	153	154	.	.	.	O

O	155	158	The	The	DT	B-NP
O	159	169	population	population	NN	I-NP
O	170	177	studied	study	VBN	B-VP
O	178	181	was	be	VBD	B-VP
O	182	195	predominantly	predominantly	RB	B-ADVP
O	196	199	not	not	RB	B-ADJP
O	200	203	HIV	HIV	NN	I-ADJP
O	204	212	infected	infected	JJ	I-ADJP
O	213	214	(	(	(	O
O	214	216	92	92	CD	B-NP
O	216	217	%	%	NN	I-NP
O	217	218	)	)	)	O
O	218	219	,	,	,	O
O	220	223	and	and	CC	O
O	224	226	by	by	IN	B-PP
O	227	230	the	the	DT	B-NP
O	231	236	study	study	NN	I-NP
O	237	242	entry	entry	NN	I-NP
O	243	251	criteria	criterion	NNS	I-NP
O	251	252	,	,	,	O
O	253	258	their	their	PRP$	B-NP
O	259	270	probability	probability	NN	I-NP
O	271	273	of	of	IN	B-PP
O	274	283	infection	infection	NN	B-NP
O	284	287	was	be	VBD	B-VP
O	288	298	considered	consider	VBN	I-VP
O	299	301	to	to	TO	I-VP
O	302	304	be	be	VB	I-VP
O	305	308	low	low	JJ	B-ADJP
O	308	309	.	.	.	O

O	310	313	The	The	DT	B-NP
O	314	318	risk	risk	NN	I-NP
O	319	329	categories	category	NNS	I-NP
O	330	338	assigned	assign	VBN	B-VP
O	339	341	at	at	IN	B-PP
O	342	345	the	the	DT	B-NP
O	346	350	time	time	NN	I-NP
O	351	353	of	of	IN	B-PP
O	354	359	study	study	NN	B-NP
O	360	365	entry	entry	NN	I-NP
O	366	370	were	be	VBD	B-VP
O	371	379	combined	combine	VBN	I-VP
O	380	384	into	into	IN	B-PP
O	385	391	groups	group	NNS	B-NP
O	392	395	for	for	IN	B-PP
O	396	404	analysis	analysis	NN	B-NP
O	404	405	,	,	,	O
O	406	411	based	base	VBN	B-PP
O	412	414	on	on	IN	B-PP
O	415	418	the	the	DT	B-NP
O	419	433	predisposition	predisposition	NN	I-NP
O	434	437	for	for	IN	B-PP
O	438	441	PCP	PCP	NN	B-NP
O	441	442	.	.	.	O

O	443	446	The	The	DT	B-NP
O	447	455	analysis	analysis	NN	I-NP
O	456	462	groups	group	NNS	I-NP
O	463	467	were	be	VBD	B-VP
O	468	470	as	as	RB	B-ADVP
O	471	478	follows	follow	VBZ	B-VP
O	478	479	:	:	:	O
O	480	481	(	(	(	B-LST
O	481	482	i	i	LS	I-LST
O	482	483	)	)	)	O
O	484	487	HIV	HIV	NN	B-NP
O	487	488	/	/	SYM	B-NP
O	488	492	AIDS	AIDS	NN	I-NP
O	492	493	,	,	,	O
O	494	495	(	(	(	B-LST
O	495	497	ii	ii	LS	I-LST
O	497	498	)	)	)	O
B-Organ	499	503	lung	lung	NN	B-NP
O	504	514	transplant	transplant	NN	I-NP
O	515	516	(	(	(	O
O	516	519	one	one	CD	B-NP
O	520	527	subject	subject	NN	I-NP
O	528	532	with	with	IN	B-PP
O	533	534	a	a	DT	B-NP
O	535	539	dual	dual	JJ	I-NP
B-Organ	540	545	organ	organ	NN	I-NP
O	546	556	transplant	transplant	NN	I-NP
O	557	558	[	[	(	O
B-Organ	558	562	lung	lung	NN	B-NP
O	562	563	/	/	SYM	B-NP
B-Organ	563	569	kidney	kidney	NN	I-NP
O	569	570	]	]	)	O
O	571	574	was	be	VBD	B-VP
O	575	583	included	include	VBN	I-VP
O	584	586	in	in	IN	B-PP
O	587	591	this	this	DT	B-NP
O	592	600	category	category	NN	I-NP
O	600	601	)	)	)	O
O	601	602	,	,	,	O
O	603	604	(	(	(	B-LST
O	604	607	iii	iii	LS	I-LST
O	607	608	)	)	)	O
O	609	612	all	all	DT	B-NP
O	613	618	other	other	JJ	I-NP
B-Organ	619	624	organ	organ	NN	I-NP
O	625	636	transplants	transplant	NNS	I-NP
O	637	640	and	and	CC	O
B-Cell	641	651	allogeneic	allogeneic	JJ	B-NP
I-Cell	652	665	hematopoietic	hematopoietic	JJ	I-NP
I-Cell	666	670	stem	stem	NN	I-NP
I-Cell	671	675	cell	cell	NN	I-NP
O	676	687	transplants	transplant	NNS	I-NP
O	688	689	(	(	(	O
O	689	693	HSCT	HSCT	NN	B-NP
O	693	694	)	)	)	O
O	694	695	,	,	,	O
O	696	697	(	(	(	B-LST
O	697	699	iv	iv	LS	I-LST
O	699	700	)	)	)	O
B-Cancer	701	709	leukemia	leukemia	NN	B-NP
O	709	710	,	,	,	O
O	711	716	other	other	JJ	B-NP
O	717	730	hematological	hematological	JJ	I-NP
O	731	740	disorders	disorder	NNS	I-NP
O	740	741	,	,	,	O
O	742	745	and	and	CC	O
O	746	756	autologous	autologous	JJ	B-NP
O	757	761	HSCT	HSCT	NN	I-NP
O	761	762	,	,	,	O
O	763	764	(	(	(	O
O	764	765	v	v	NN	B-NP
O	765	766	)	)	)	O
O	767	772	other	other	JJ	B-NP
B-Cancer	773	778	solid	solid	JJ	I-NP
I-Cancer	779	785	tumors	tumor	NNS	I-NP
O	785	786	,	,	,	O
O	787	790	and	and	CC	O
O	791	792	(	(	(	B-LST
O	792	794	vi	vi	LS	I-LST
O	794	795	)	)	)	O
O	796	801	other	other	JJ	B-NP
O	802	814	nonmalignant	nonmalignant	JJ	I-NP
O	815	825	conditions	condition	NNS	I-NP
O	825	826	.	.	.	O

O	827	832	Table	Table	JJ	B-NP
O	833	834	1	1	CD	I-NP
O	834	835	.	.	.	O

O	836	843	Subject	Subject	NN	B-NP
O	844	854	enrollment	enrollment	NN	I-NP
O	854	855	,	,	,	O
O	856	867	disposition	disposition	NN	B-NP
O	867	868	,	,	,	O
O	869	872	and	and	CC	O
O	873	885	demographics	demographic	NNS	B-NP
O	886	888	by	by	IN	B-PP
O	889	894	sitea	sitea	NN	B-NP

O	895	909	Characteristic	Characteristic	NNP	B-NP
O	910	916	Valueb	Valueb	NNP	I-NP

O	917	921	Site	Site	NN	B-NP
O	922	923	1	1	CD	I-NP
O	924	928	Site	Site	NN	I-NP
O	929	930	2	2	CD	B-NP
O	931	935	Site	Site	NN	I-NP
O	936	937	3	3	CD	B-NP
O	938	942	Site	Site	NN	I-NP
O	943	944	4	4	CD	B-NP

O	945	955	Enrollment	Enrollment	NN	B-NP

O	956	962	Unique	Unique	JJ	B-NP
O	963	971	subjects	subject	NNS	I-NP
O	972	974	18	18	CD	B-NP
O	975	977	29	29	CD	I-NP
O	978	980	22	22	CD	I-NP
O	981	983	62	62	CD	I-NP

O	984	992	Subjects	Subject	NNS	B-NP
O	993	1001	entering	enter	VBG	B-VP
O	1002	1006	into	into	IN	B-PP
O	1007	1014	primary	primary	JJ	B-NP
O	1015	1024	analysisc	analysisc	NN	I-NP
O	1025	1027	18	18	CD	I-NP
O	1028	1030	22	22	CD	I-NP
O	1031	1033	22	22	CD	I-NP
O	1034	1036	48	48	CD	I-NP

O	1037	1045	Subjects	Subject	NNS	B-NP
O	1046	1050	with	with	IN	B-PP
O	1051	1057	repeat	repeat	NN	B-NP
O	1058	1064	visits	visit	NNS	I-NP
O	1065	1066	0	0	CD	B-NP
O	1067	1068	0	0	CD	I-NP
O	1069	1070	0	0	CD	I-NP
O	1071	1073	16	16	CD	I-NP

O	1074	1076	No	No	DT	B-NP
O	1076	1077	.	.	NN	I-NP
O	1078	1080	of	of	IN	B-PP
B-Tissue	1081	1088	samples	sample	NNS	B-NP
O	1089	1096	assayed	assay	VBD	B-VP
O	1097	1099	18	18	CD	B-NP
O	1100	1102	22	22	CD	I-NP
O	1103	1105	22	22	CD	I-NP
O	1106	1108	70	70	CD	I-NP

O	1109	1115	Gender	Gender	NNP	B-NP

O	1116	1120	Male	Male	JJ	B-NP
O	1121	1122	7	7	CD	I-NP
O	1123	1125	10	10	CD	I-NP
O	1126	1128	13	13	CD	I-NP
O	1129	1131	29	29	CD	I-NP

O	1132	1138	Female	Female	JJ	B-NP
O	1139	1141	11	11	CD	I-NP
O	1142	1144	12	12	CD	I-NP
O	1145	1146	9	9	CD	I-NP
O	1147	1149	19	19	CD	I-NP

O	1150	1154	Race	Race	NNP	B-NP

O	1155	1164	Caucasian	Caucasian	JJ	B-NP
O	1165	1167	12	12	CD	I-NP
O	1168	1169	4	4	CD	I-NP
O	1170	1171	0	0	CD	I-NP
O	1172	1174	48	48	CD	I-NP

O	1175	1180	Black	Black	NNP	B-NP
O	1181	1182	6	6	CD	I-NP
O	1183	1185	13	13	CD	I-NP
O	1186	1187	0	0	CD	I-NP
O	1188	1189	0	0	CD	I-NP

O	1190	1195	Other	Other	JJ	O
O	1196	1197	(	(	(	O
O	1197	1205	nonwhite	nonwhite	JJ	B-ADJP
O	1205	1206	)	)	)	O
O	1207	1208	0	0	CD	B-NP
O	1209	1210	5	5	CD	I-NP
O	1211	1212	0	0	CD	I-NP
O	1213	1214	0	0	CD	I-NP

O	1215	1217	No	No	DT	B-NP
O	1218	1222	data	datum	NNS	I-NP
O	1223	1224	0	0	CD	B-NP
O	1225	1226	0	0	CD	I-NP
O	1227	1229	22	22	CD	I-NP
O	1230	1231	0	0	CD	I-NP

O	1232	1236	Mean	Mean	NN	B-NP
O	1237	1238	(	(	(	O
O	1238	1243	range	range	NN	B-NP
O	1243	1244	)	)	)	O
O	1245	1248	age	age	NN	B-NP
O	1249	1250	(	(	(	O
O	1250	1252	yr	yr	NN	B-NP
O	1252	1253	)	)	)	O
O	1254	1256	57	57	CD	B-NP
O	1257	1258	(	(	(	O
O	1258	1260	26	26	CD	B-NP
O	1260	1261	-	-	HYPH	O
O	1261	1263	78	78	CD	B-NP
O	1263	1264	)	)	)	O
O	1265	1267	54	54	CD	B-NP
O	1268	1269	(	(	(	O
O	1269	1271	21	21	CD	B-NP
O	1271	1272	-	-	HYPH	O
O	1272	1274	75	75	CD	B-NP
O	1274	1275	)	)	)	O
O	1276	1278	52	52	CD	B-NP
O	1279	1280	(	(	(	O
O	1280	1282	26	26	CD	B-NP
O	1282	1283	-	-	HYPH	O
O	1283	1285	74	74	CD	B-NP
O	1285	1286	)	)	)	O
O	1287	1289	56	56	CD	B-NP
O	1290	1291	(	(	(	O
O	1291	1293	23	23	CD	B-NP
O	1293	1294	-	-	HYPH	O
O	1294	1296	73	73	CD	B-NP
O	1296	1297	)	)	)	O

O	1298	1305	Pretest	Pret	JJS	B-NP
O	1306	1317	probability	probability	NN	I-NP
O	1318	1320	of	of	IN	B-PP
O	1321	1324	PCP	PCP	NN	B-NP

O	1325	1333	Moderate	Moderate	NNP	B-NP
O	1334	1335	0	0	CD	I-NP
O	1336	1337	3	3	CD	I-NP
O	1338	1339	4	4	CD	I-NP
O	1340	1341	0	0	CD	I-NP

O	1342	1345	Low	Low	RB	B-NP
O	1346	1348	18	18	CD	I-NP
O	1349	1351	19	19	CD	I-NP
O	1352	1354	18	18	CD	I-NP
O	1355	1357	48	48	CD	I-NP

B-Tissue	1358	1364	Sample	Sample	NN	B-NP
O	1365	1369	type	type	NN	I-NP

O	1370	1373	BAL	BAL	NN	B-NP
O	1374	1376	18	18	CD	I-NP
O	1377	1379	20	20	CD	I-NP
O	1380	1382	20	20	CD	I-NP
O	1383	1385	43	43	CD	I-NP

B-Organism_substance	1386	1392	Sputum	Sputum	NNP	B-NP
O	1393	1394	0	0	CD	I-NP
O	1395	1396	1	1	CD	I-NP
O	1397	1398	1	1	CD	I-NP
O	1399	1400	0	0	CD	I-NP

O	1401	1406	Other	Other	JJ	B-NP
O	1407	1410	LRT	LRT	NNP	I-NP
O	1411	1412	0	0	CD	I-NP
O	1413	1414	1	1	CD	I-NP
O	1415	1416	1	1	CD	I-NP
O	1417	1418	5	5	CD	I-NP

O	1419	1421	At	At	IN	B-PP
O	1421	1422	-	-	HYPH	B-NP
O	1422	1426	risk	risk	NN	I-NP
O	1427	1432	group	group	NN	I-NP

O	1433	1436	HIV	HIV	NN	B-NP
O	1436	1437	/	/	SYM	I-NP
O	1437	1441	AIDS	AIDS	NN	I-NP
O	1442	1443	0	0	CD	I-NP
O	1444	1445	3	3	CD	I-NP
O	1446	1447	6	6	CD	I-NP
O	1448	1449	0	0	CD	I-NP

B-Organ	1450	1454	Lung	Lung	NN	B-NP
O	1455	1465	transplant	transplant	NN	I-NP
O	1466	1467	8	8	CD	I-NP
O	1468	1469	0	0	CD	I-NP
O	1470	1471	1	1	CD	I-NP
O	1472	1474	31	31	CD	I-NP

O	1475	1480	Other	Other	JJ	B-NP
O	1481	1492	transplants	transplant	NNS	I-NP
O	1493	1494	1	1	CD	I-NP
O	1495	1496	7	7	CD	I-NP
O	1497	1498	3	3	CD	I-NP
O	1499	1500	0	0	CD	I-NP

B-Cancer	1501	1509	Leukemia	Leukemia	NNP	B-NP
O	1510	1511	1	1	CD	I-NP
O	1512	1513	1	1	CD	I-NP
O	1514	1515	7	7	CD	I-NP
O	1516	1517	0	0	CD	I-NP

O	1518	1523	Other	Other	JJ	B-NP
B-Cancer	1524	1529	solid	solid	JJ	I-NP
I-Cancer	1530	1536	tumors	tumor	NNS	I-NP
O	1537	1538	2	2	CD	B-NP
O	1539	1540	1	1	CD	I-NP
O	1541	1542	1	1	CD	I-NP
O	1543	1544	7	7	CD	I-NP

O	1545	1550	Other	Other	JJ	B-NP
O	1551	1563	nonmalignant	nonmalignant	JJ	I-NP
O	1564	1574	conditions	condition	NNS	I-NP
O	1575	1576	6	6	CD	B-NP
O	1577	1579	10	10	CD	I-NP
O	1580	1581	4	4	CD	I-NP
O	1582	1584	10	10	CD	I-NP

O	1585	1586	a	a	DT	B-NP

O	1587	1590	The	The	DT	B-NP
O	1591	1598	testing	testing	NN	I-NP
O	1599	1602	and	and	CC	I-NP
O	1603	1613	enrollment	enrollment	NN	I-NP
O	1614	1619	sites	site	NNS	I-NP
O	1620	1623	for	for	IN	B-PP
O	1624	1627	the	the	DT	B-NP
O	1628	1633	study	study	NN	I-NP
O	1634	1638	were	be	VBD	B-VP
O	1639	1643	Duke	Duke	NNP	B-NP
O	1644	1654	University	University	NNP	I-NP
O	1655	1661	School	School	NNP	I-NP
O	1662	1664	of	of	IN	B-PP
O	1665	1673	Medicine	Medicine	NNP	B-NP
O	1673	1674	,	,	,	O
O	1675	1681	Durham	Durham	NNP	B-NP
O	1681	1682	,	,	,	O
O	1683	1685	NC	NC	NNP	B-NP
O	1685	1686	;	;	:	O
O	1687	1693	Albert	Albert	NNP	B-NP
O	1694	1702	Einstein	Einstein	NNP	I-NP
O	1703	1710	College	College	NNP	I-NP
O	1711	1713	of	of	IN	B-PP
O	1714	1722	Medicine	Medicine	NNP	B-NP
O	1723	1726	and	and	CC	O
O	1727	1737	Montefiore	Montefiore	NNP	B-NP
O	1738	1745	Medical	Medical	NNP	I-NP
O	1746	1752	Center	Center	NNP	I-NP
O	1752	1753	,	,	,	O
O	1754	1759	Bronx	Bronx	NNP	B-NP
O	1759	1760	,	,	,	O
O	1761	1763	NY	NY	NNP	B-NP
O	1763	1764	;	;	:	O
O	1765	1771	Centre	Centre	NNP	B-NP
O	1772	1783	Hospitalier	Hospitalier	NNP	I-NP
O	1784	1797	Universitaire	Universitaire	NNP	I-NP
O	1798	1805	Vaudois	Vaudois	NNP	I-NP
O	1806	1809	and	and	CC	O
O	1810	1820	University	University	NNP	B-NP
O	1821	1823	of	of	IN	B-PP
O	1824	1832	Lausanne	Lausanne	NNP	B-NP
O	1832	1833	,	,	,	O
O	1834	1842	Lausanne	Lausanne	NNP	B-NP
O	1842	1843	,	,	,	O
O	1844	1855	Switzerland	Switzerland	NNP	B-NP
O	1855	1856	;	;	:	O
O	1857	1860	and	and	CC	O
O	1861	1873	Medizinische	Medizinische	NNP	B-NP
O	1874	1885	Universitat	Universitat	NNP	I-NP
O	1886	1889	and	and	CC	O
O	1890	1907	Landeskrankenhaus	Landeskrankenhaus	NNP	B-NP
O	1908	1915	Natters	Natters	NNP	I-NP
O	1915	1916	,	,	,	O
O	1917	1926	Innsbruck	Innsbruck	NNP	B-NP
O	1926	1927	,	,	,	O
O	1928	1935	Austria	Austria	NNP	B-NP
O	1935	1936	.	.	.	O

O	1937	1938	b	b	NN	B-NP

O	1939	1945	Except	Except	IN	B-PP
O	1946	1951	where	where	WRB	B-ADVP
O	1952	1961	otherwise	otherwise	RB	B-VP
O	1962	1971	indicated	indicate	VBN	I-VP
O	1971	1972	,	,	,	O
O	1973	1979	values	value	NNS	B-NP
O	1980	1983	are	be	VBP	B-VP
O	1984	1991	numbers	number	NNS	B-NP
O	1992	1994	of	of	IN	B-PP
O	1995	2003	patients	patient	NNS	B-NP
O	2003	2004	.	.	.	O

O	2005	2006	c	c	NN	B-NP

O	2007	2015	Subjects	Subject	NNS	B-NP
O	2016	2020	were	be	VBD	B-VP
O	2021	2029	excluded	exclude	VBN	I-VP
O	2030	2034	from	from	IN	B-PP
O	2035	2043	analysis	analysis	NN	B-NP
O	2044	2046	if	if	IN	B-SBAR
O	2047	2051	they	they	PRP	B-NP
O	2052	2060	withdrew	withdraw	VBD	B-VP
O	2061	2068	consent	consent	NN	B-NP
O	2069	2071	or	or	CC	B-PP
O	2072	2074	if	if	IN	B-SBAR
O	2075	2080	there	there	EX	B-NP
O	2081	2084	was	be	VBD	B-VP
O	2085	2095	inadequate	inadequate	JJ	B-NP
B-Tissue	2096	2102	sample	sample	NN	I-NP
O	2103	2107	left	leave	VBN	B-VP
O	2108	2111	for	for	IN	B-PP
O	2112	2115	PCR	PCR	NN	B-NP
O	2116	2123	testing	testing	NN	I-NP
O	2123	2124	.	.	.	O

